drugset / Trial / NCT06923761
EMITT-1 (ERAP Mediated Immunopeptidome Targeting Trial - 1)
Non-randomizedSequentialOpen-labelTreatment
Summary
This is a Phase I/II, open-label, first-in human study of GRWD5769 alone, and in combination with another anti-cancer agent in advanced solid cancers.
Timeline
- Start
- 2023-05-21
- Primary completion
- 2027-04-30
- Completion
- 2028-04-30
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | GRWD5769 | Unknown | — | Intravenous |
| Background | Cemiplimab | Monoclonal antibody | — | Intravenous |